Guy Bormans
YOU?
Author Swipe
View article: RBIO-09. Preclinical evaluation of the synergistic effect of heat shock protein 90 inhibitors with temozolomide and external beam radiotherapy in glioblastoma models
RBIO-09. Preclinical evaluation of the synergistic effect of heat shock protein 90 inhibitors with temozolomide and external beam radiotherapy in glioblastoma models Open
INTRODUCTION Heat shock protein 90 (Hsp90) is a molecular chaperone that interacts with other co-chaperones to stabilize, mature and (re)fold proteins1. Its overexpression in cancer cells makes it attractive as a chemotherapeutic target. H…
View article: [11C]HSP990 PET as a translational tool to investigate the role of Hsp90 in tumours and support the development of Hsp90 therapeutics
[11C]HSP990 PET as a translational tool to investigate the role of Hsp90 in tumours and support the development of Hsp90 therapeutics Open
[11C]HSP990 is a promising tracer for identifying Hsp90-overexpressing tumours and may hold potential for patient stratification, prognosis, and therapy monitoring of novel Hsp90 therapeutics. High healthy brain uptake of this tracer precl…
View article: In vivo imaging of heat shock protein 90: Diagnostic tool and support for Hsp90-targeted therapy
In vivo imaging of heat shock protein 90: Diagnostic tool and support for Hsp90-targeted therapy Open
The molecular chaperone heat shock protein 90 (Hsp90), essential for protein homeostasis and cellular stress response, has emerged as a promising therapeutic target across various diseases, including cancer, neurodegenerative disorders, an…
View article: In Vivo Visualization and Quantification of Brain Heat Shock Protein 90 with [<sup>11</sup>C]HSP990 in Healthy Aging and Neurodegeneration
In Vivo Visualization and Quantification of Brain Heat Shock Protein 90 with [<sup>11</sup>C]HSP990 in Healthy Aging and Neurodegeneration Open
Heat shock protein 90 (Hsp90) is essential for maintaining cellular proteostasis and may play an important role in the development of neurodegenerative proteinopathies. Therefore, we aimed to develop an Hsp90-specific PET brain tracer to q…
View article: Radiosynthesis and Evaluation of [<sup>18</sup>F]FEHSP990 as Novel PET Tracer for Hsp90 PET Imaging
Radiosynthesis and Evaluation of [<sup>18</sup>F]FEHSP990 as Novel PET Tracer for Hsp90 PET Imaging Open
Heat shock protein 90 (Hsp90) is a critical chaperone in the protein quality control system, essential for maintaining cellular proteostasis. Aberrant Hsp90 function has been implicated in cancer and neurodegenerative disorders, making it …
View article: Indium-111-Labeled Single-Domain Antibody for <i>In Vivo</i> CXCR4 Imaging Using Single-Photon Emission Computed Tomography
Indium-111-Labeled Single-Domain Antibody for <i>In Vivo</i> CXCR4 Imaging Using Single-Photon Emission Computed Tomography Open
C-X-C chemokine receptor type 4 (CXCR4) is highly expressed in a range of pathologies, including cancers like multiple myeloma and non-Hodgkin lymphoma, inflammatory diseases such as rheumatoid arthritis, and viral infections like HIV. Cur…
View article: Selective PET imaging of CXCR4 using the Al18F-labeled antagonist LY2510924
Selective PET imaging of CXCR4 using the Al18F-labeled antagonist LY2510924 Open
[18F]AlF-NOTA-SC exhibited CXCR4-specific uptake in vitro and in vivo, with fast and persistent tumor accumulation, making it a strong candidate for clinical translation as an 18F-alternative to [68Ga]PentixaFor.
View article: Increasing brain half-life of antibodies by additional binding to myelin oligodendrocyte glycoprotein, a CNS specific protein
Increasing brain half-life of antibodies by additional binding to myelin oligodendrocyte glycoprotein, a CNS specific protein Open
Background Therapeutic antibodies for the treatment of neurological disease show great potential, but their applications are rather limited due to limited brain exposure. The most well-studied approach to enhance brain influx of protein th…
View article: HDAC6 inhibitors sensitize resistant t(11;14) multiple myeloma cells to a combination of bortezomib and BH3 mimetics
HDAC6 inhibitors sensitize resistant t(11;14) multiple myeloma cells to a combination of bortezomib and BH3 mimetics Open
Not available.
View article: Translational Preclinical PET Imaging and Metabolic Evaluation of a New Cannabinoid 2 Receptor (CB<sub>2</sub>R) Radioligand, (<i>Z</i>)-<i>N</i>-(3-(2-(2-[<sup>18</sup>F]Fluoroethoxy)ethyl)-4,5-dimethylthiazol-2(3<i>H</i>)-ylidene)-2,2,3,3-tetramethylcyclopropane-1-carboxamide
Translational Preclinical PET Imaging and Metabolic Evaluation of a New Cannabinoid 2 Receptor (CB<sub>2</sub>R) Radioligand, (<i>Z</i>)-<i>N</i>-(3-(2-(2-[<sup>18</sup>F]Fluoroethoxy)ethyl)-4,5-dimethylthiazol-2(3<i>H</i>)-ylidene)-2,2,3,3-tetramethylcyclopropane-1-carboxamide Open
We have previously developed seven fluorinated analogues of A-836339 as new PET tracers for cannabinoid type 2 receptor (CB2R) imaging, among which (Z)-N-(3-(2-(2-[18F]fluoroethoxy)ethyl)-4,5-dimethylthiazol-2(3H)-ylidene)-2,2,3,3-tetramet…
View article: Clinical impact of using [ <scp> <sup>18</sup> F </scp> ] <scp>AlF</scp> ‐ <scp>NOTA</scp> ‐octreotide <scp>PET</scp> / <scp>CT</scp> instead of [ <scp> <sup>68</sup> Ga </scp> ]Ga‐ <scp>DOTA</scp> ‐ <scp>SSA PET</scp> / <scp>CT</scp> : Secondary endpoint analysis of a multicenter, prospective trial
Clinical impact of using [ <span> <sup>18</sup> F </span> ] <span>AlF</span> ‐ <span>NOTA</span> ‐octreotide <span>PET</span> / <span>CT</span> instead of [ <span> <sup>68</sup> Ga </span> ]Ga‐ <span>DOTA</span> ‐ <span>SSA PET</span> / <span>CT</span> : Secondary endpoint analysis of a multicenter, prospective trial Open
[ 18 F]AlF‐NOTA‐octreotide ([ 18 F]AlF‐OC) is a promising alternative for [ 68 Ga]Ga‐DOTA‐somatostatin analogs (SSAs) in positron emission tomography (PET) imaging of the somatostatin receptor (SSTR). Our aim is to assess changes in TNM st…
View article: Synthesis, Structure–Activity Relationships, Radiofluorination, and Biological Evaluation of [<sup>18</sup>F]RM365, a Novel Radioligand for Imaging the Human Cannabinoid Receptor Type 2 (CB2R) in the Brain with PET
Synthesis, Structure–Activity Relationships, Radiofluorination, and Biological Evaluation of [<sup>18</sup>F]RM365, a Novel Radioligand for Imaging the Human Cannabinoid Receptor Type 2 (CB2R) in the Brain with PET Open
The development of cannabinoid receptor type 2 (CB2R) PET radioligands has been intensively explored due to the pronounced CB2R upregulation under various pathological conditions. Herein, we report on the synthesis of a series of CB2R affi…
View article: Radiopharmaceuticals for Cancer Imaging and Therapy
Radiopharmaceuticals for Cancer Imaging and Therapy Open
Nuclear medicine has emerged as a pivotal player in cancer patient care, revolutionizing the way cancer is detected, diagnosed, monitored, and treated [...]
View article: Author Correction: Reverse engineering synthetic antiviral amyloids
Author Correction: Reverse engineering synthetic antiviral amyloids Open
status: Published
View article: 3p-C-NETA-TATE: A Potential Somatostatin Analogue for Diagnostic and Therapeutic SSTR2 Targeting Radiopharmaceuticals
3p-C-NETA-TATE: A Potential Somatostatin Analogue for Diagnostic and Therapeutic SSTR2 Targeting Radiopharmaceuticals Open
Introduction: Somatostatin-based radiopharmaceuticals (e.g., [68Ga] Ga-DOTATATE and [177Lu] Lu-DOTATATE) have been used successfully to diagnose, monitor, and treat patients with neuroendocrine tumors. [18F] AlF-NOTA-octreotide, a promisin…